Abstract: Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis characterized by transepidermal elimination of altered collagen fibers. The etiology and pathophysiology of ARPC remain elusive, and there is no gold standard for its treatment. This study comprehensively reviews the clinical manifestations, epidemiology, etiology, pathophysiology, diagnosis, and treatment of ARPC, with a focus on recent advances in pathophysiology, dermoscopic findings, and the application of biologic agents and small molecule drugs.

Key words: acquired reactive perforating collagenosis, type 2 inflammation, dermatoscope, biologic agents, small molecule drugs